FibroGen Stock News

The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease (CKD). The letter indicates the FD

SAN FRANCISCO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New

FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q2 2021 Results - Earnings Call Transcript

FibroGen (FGEN) delivered earnings and revenue surprises of -202.08% and -68.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FDA approval of roxadustat seems unlikely.

SUZHOU, China and SAN FRANCISCO, July 19, 2021 (GLOBE NEWSWIRE) -- Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with

An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns.

FibroGen (FGEN) stock is falling hard on Friday after the company received the results of an FDA review for one of its drugs. The post FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fal

FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.

FibroGen, Inc. (NASDAQ: FGEN) shares are trading lower after an FDA Advisory Committee panel voted against approval of the company's New Drug Application for roxadustat to treat anemia due to chronic

AstraZeneca PLC has disclosed Friday that a U.S. Food and Drug Administration advisory committee has voted 13 to 1 not to support approval of roxadustat for the treatment of anaemia in chronic kidney

FibroGen, Inc.'s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen's AdCom Snub  FibroGen said late Thursday the Food and Drug Administration's Cardiovascular a

Yesterday, the U.S. FDA voted not to approve Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients.

AstraZeneca PLC (LON:AZN) faces rejection from the US drug regulator for its application for a novel new drug to treat anaemia resulting from chronic kidney disease (CKD). The Food and Drug Administr